drugset / Trial / NCT00004811
Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis
Phase 1/2
Completed
7 enrolled
National Center for Research Resources (NCRR)
National Institute of Allergy and Infectious Diseases (NIAID) · collabUniversity of Alabama at Birmingham · collab
Treatment
Summary
OBJECTIVES: I. Evaluate the tolerance of patients with blastomycosis, histoplasmosis, and sporotrichosis to different doses of itraconazole (R51,211). II. Determine levels of itraconazole in serum and other body fluids. III. Assess the course of illness during itraconazole therapy. IV. Determine the dosage of itraconazole that is safe and well tolerated by 80%-90% of patients and estimate the potential of this dosage for use in future comparative trials.
Timeline
- Start
- 1985-03
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itraconazole | Small molecule | — | Oral |